Gus Theodos, MD
Interventional Cardiology · Saint Louis, MONPI 1053401422
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Boston Scientific at 40.7% of the total. 2025 is the largest year on record at $67,897, 3.0 times the $22,861 reported in 2019. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 898 payments — averaging $183.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$67K
- Edwards Lifesciences$60K
- Penumbra, Inc.$19K
- Asahi Intecc USA, Inc.$6K
- Abbott$4K
- Abiomed$2K
- plus $8K from 28 others
Across 15 payments — averaging $1968.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$30K
What the payments were for
- Consulting fees$40,49625%
- Speaking & faculty fees$76,28846%
- Travel & lodging$23,16614%
- Food & beverage$24,88915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 155 | $67,148 |
| Edwards Lifesciences | 315 | $59,846 |
| Penumbra, Inc. | 39 | $18,533 |
| Asahi Intecc USA, Inc. | 38 | $5,744 |
| Abbott | 59 | $3,974 |
| Abiomed | 51 | $2,054 |
| Philips North America LLC | 17 | $1,461 |
| Medtronic(2 entities) | 21 | $1,399 |
| Shockwave Medical, Inc | 47 | $1,180 |
| Teleflex LLC | 9 | $750 |
| Biotronik Inc. | 6 | $397 |
| Amgen | 19 | $347 |
| Novartis | 14 | $283 |
| AstraZeneca | 11 | $228 |
| Chiesi USA, Inc. | 13 | $196 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $195 |
| Boehringer Ingelheim | 9 | $138 |
| E.r. Squibb & Sons, L.L.C. | 9 | $135 |
| Siemens Medical Solutions USA, Inc. | 7 | $117 |
| Cardiva Medical, Inc. | 5 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| ZOLL Circulation Inc | 6 | $80 |
| Pfizer | 5 | $64 |
| Cardiovascular Systems Inc. | 4 | $50 |
| Heartflow, Inc. | 3 | $45 |
| Cardinal Health 200 LLC | 2 | $42 |
| Cvrx, Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Inari Medical, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $29 |
| Z-medica, LLC | 1 | $21 |
| Cook Medical LLC | 1 | $13 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$22,419
- PASCAL$18,096
- Indigo$17,979
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$14,765
- Edwards SAPIEN 3 Transcatheter Heart Valve$10,841
- ASAHI PTCA Guide Wire$4,236
- SAPIEN 3 Ultra RESILIA$1,536
- EVOQUE$1,410
- Indigo System$1,310
- GENERAL - THERAPIES$1,147
- (9525) Intracardiac Und$1,084
- TENDYNE$924
- Impella$819
- OPTICROSS$800
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$750
- Micra$692
- AVVIGO Guidance System$663
- GUIDEZILLA$600
- Asahi Coronary Wires$500
- Watchman$435
How this compares
$164,838 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $170,060 |
| BrilintaTicagrelor | 116 | $74,941 |
| EntrestoSacubitril/Valsartan | 59 | $49,530 |
| Repatha SureclickEvolocumab | 61 | $42,916 |
| XareltoRivaroxaban | 32 | $31,031 |
| JardianceEmpagliflozin | 29 | $30,436 |
| FarxigaDapagliflozin Propanediol | 18 | $18,025 |
| Praluent PenAlirocumab | 11 | $15,475 |
| ClopidogrelClopidogrel Bisulfate | 428 | $3,354 |
| Rosuvastatin Calcium | 185 | $2,506 |
| Metoprolol Succinate | 246 | $2,271 |
| Prasugrel Hcl | 13 | $2,101 |
| Atorvastatin Calcium | 217 | $1,941 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 81 | $1,109 |
| Isosorbide Dinitrate | 21 | $870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $170,060176 claims |
| AstraZenecaBrilinta, Farxiga | $228 | $92,966134 claims |
| NovartisEntresto | $283 | $49,53059 claims |
| Johnson & JohnsonXarelto | $31 | $31,03132 claims |
| Boehringer IngelheimJardiance | $138 | $30,43629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
- Anthony SonnSaint Louis$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.